Skip to main content
Clinical Trials/JPRN-UMIN000026760
JPRN-UMIN000026760
Completed
未知

A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease - A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease

ipro Corporation0 sites135 target enrollmentMarch 29, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ipro Corporation
Enrollment
135
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 29, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ipro Corporation

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Acute myocardial infarction within 72 hour after onset; acute cardiac failure; pregnancy or lactation; renal dysfunction (serum creatinine \>1\.5 mg/dl); low left ventricular function (left ventricular ejection fraction \<30%) Contraindications or known intolerance to antiplatelet agents, paclitaxel, or contrast agents Lesions in the left main branch; patients meeting the criteria for coronary artery bypass graft (CABG); lesions 2mm or shorter from a bifurcation; multiple lesions in a single branch; patients with highly calcified lesions that were difficult to dilate with a balloon; high\-grade bend lesions 90% or more; Previously undergone placement of a paclitaxel\-eluting stent or had undergone DES placement within the preceding 24 weeks

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Multicenter Randomized Comparison of Paclitaxel-eluting Balloon Catheter with Conventional Balloon Angioplasty in Patients with Bare-metal Stent Restenosis and Drug-eluting Stent RestenosisIschemic heart disease
JPRN-UMIN000008681ipro Corporation (Osaka, Japan)210
Active, not recruiting
Not Applicable
Randomized multicenter trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteration - VIPP
EUCTR2005-004695-20-DERoche Pharma AG300
Active, not recruiting
Not Applicable
Trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteratioPrevention of cytomegalovirus (CMV) disease in kidney transplant recipientsMedDRA version: 17.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2005-004695-20-ATRoche Pharma AG300
Recruiting
Phase 3
Multicenter double-blind randomized comparative parallel study with concomitant therapy of 3 drugs, aprepitant + dexamethasone+palonosetron or aprepitant + dexamethasone+ granisetron, for prevention of nausea/vomiting in breast cancer patients receiving AC therapyBreast Cancer
JPRN-UMIN000007882Juntendo Clinical Research Support Center660
Active, not recruiting
Phase 1
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II) - HIDIT-IITo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 9.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis delta
EUCTR2008-005560-13-GRMedizinische Hochschule Hannover70